Nature Communications (Apr 2022)
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation
- Zheqi Li,
- Olivia McGinn,
- Yang Wu,
- Amir Bahreini,
- Nolan M. Priedigkeit,
- Kai Ding,
- Sayali Onkar,
- Caleb Lampenfeld,
- Carol A. Sartorius,
- Lori Miller,
- Margaret Rosenzweig,
- Ofir Cohen,
- Nikhil Wagle,
- Jennifer K. Richer,
- William J. Muller,
- Laki Buluwela,
- Simak Ali,
- Tullia C. Bruno,
- Dario A. A. Vignali,
- Yusi Fang,
- Li Zhu,
- George C. Tseng,
- Jason Gertz,
- Jennifer M. Atkinson,
- Adrian V. Lee,
- Steffi Oesterreich
Affiliations
- Zheqi Li
- Department of Pharmacology and Chemical Biology, University of Pittsburgh
- Olivia McGinn
- Womens Cancer Research Center, UPMC Hillman Cancer Center
- Yang Wu
- Womens Cancer Research Center, UPMC Hillman Cancer Center
- Amir Bahreini
- Womens Cancer Research Center, UPMC Hillman Cancer Center
- Nolan M. Priedigkeit
- Department of Pharmacology and Chemical Biology, University of Pittsburgh
- Kai Ding
- Womens Cancer Research Center, UPMC Hillman Cancer Center
- Sayali Onkar
- Womens Cancer Research Center, UPMC Hillman Cancer Center
- Caleb Lampenfeld
- Department of Immunology, University of Pittsburgh
- Carol A. Sartorius
- Department of Pathology, University of Colorado Anschutz Medical Campus
- Lori Miller
- Womens Cancer Research Center, UPMC Hillman Cancer Center
- Margaret Rosenzweig
- School of Nursing, University of Pittsburgh
- Ofir Cohen
- Department of Medical Oncology and Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Harvard Medical School
- Nikhil Wagle
- Department of Medical Oncology and Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Harvard Medical School
- Jennifer K. Richer
- Department of Pathology, University of Colorado Anschutz Medical Campus
- William J. Muller
- Goodman Cancer Centre and Departments of Biochemistry and Medicine, McGill University
- Laki Buluwela
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus
- Simak Ali
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus
- Tullia C. Bruno
- Department of Immunology, University of Pittsburgh
- Dario A. A. Vignali
- Department of Immunology, University of Pittsburgh
- Yusi Fang
- Department of Biostatistics, University of Pittsburgh
- Li Zhu
- Department of Biostatistics, University of Pittsburgh
- George C. Tseng
- Department of Biostatistics, University of Pittsburgh
- Jason Gertz
- Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah
- Jennifer M. Atkinson
- Department of Pharmacology and Chemical Biology, University of Pittsburgh
- Adrian V. Lee
- Department of Pharmacology and Chemical Biology, University of Pittsburgh
- Steffi Oesterreich
- Department of Pharmacology and Chemical Biology, University of Pittsburgh
- DOI
- https://doi.org/10.1038/s41467-022-29498-9
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 18
Abstract
Mutations of ESR1, the gene encoding the estrogen receptor alpha, are associated with acquired resistance to therapy in luminalbreast cancer. Here the authors show that ESR1 mutant tumors gain basal-like features with increased expression of basal cytokeratines and immune activation.
